Lennon RP, Zgierska AE, Miller EL, Snyder B, Keshaviah A, Hu XC, Zhou H, Van Scoy LJ. Lower intent to comply with COVID-19 public health recommendations correlates to higher disease burden in following 30 days. South Med J. 2021 Dec;114(12):744-50. doi: 10.14423/SMJ.0000000000001332
van der Wall SJ, Lip GYH, Teutsch C, Kalejs O, Lyrer P, Hall C, Dubner SJ, Diener HC, Halperin JL, Ma CS, Rothman KJ, Zint K, Zhai D, Huisman MV, GLORIA-AF Investigators. Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study. Eur J Intern Med. 2021 Sep;91:75-80. doi: 10.1016/j.ejim.2021.05.020
Lennon RP, Miller EL, Dong H, Rabago D, Zgierska A. Association of the US COVID-19 pandemic and attenuated influenza detection. South Med J. 2021 Jun;114(6):343. doi: 10.14423/SMJ.0000000000001254
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Bullard JT, Eberth JM, Arrington AK, Adams SA, Cheng X, Salloum RG. Timeliness of treatment initiation and associated survival following diagnosis of non-small-cell lung cancer in South Carolina. South Med J. 2017 Feb;110(2):107-13. doi: 10.14423/SMJ.0000000000000601
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Kim D, Lauria DT, Poulos C, Dong B, Whittington D. Effect of travel distance on household demand for typhoid vaccines: implications for planning. Int J Health Plann Manage. 2013 Mar 12;Advance Online.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.
Bushel PR, Hamadeh H, Bennett L, Sieber S, Martin K, Nuwaysir EF, Johnson K, Reynolds K, Paules RS, Afshari CA. MAPS: a microarray project system for gene expression experiment information and data validation. Bioinformatics. 2001 Jun 1;17(6):564-5.